This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMPX International（MPXI）株式概要MPXインターナショナル・コーポレーションは、カナダおよび国際的に大麻を取り扱う企業である。 詳細MPXI ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 株式の流動性は非常に低い 意味のある時価総額がありません ( CA$722K )すべてのリスクチェックを見るMPXI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceN/A該当なし内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-45m7m2016201920222025202620282031Revenue CA$6.7mEarnings CA$983.2kAdvancedSet Fair ValueView all narrativesMPX International Corporation 競合他社SugarBud Craft GrowersSymbol: TSXV:SUGR.HMarket cap: CA$718.6kJolt HealthSymbol: CNSX:JOLTMarket cap: CA$1.1mCaptor CapitalSymbol: CNSX:CPTRMarket cap: CA$767.1kHempsana HoldingsSymbol: CNSX:HMPSMarket cap: CA$591.3k価格と性能株価の高値、安値、推移の概要MPX International過去の株価現在の株価CA$052週高値CA$0.0152週安値CA$0.005ベータ01ヶ月の変化n/a3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化n/a最新ニュースBoard Change • Jul 31High number of new directorsIndependent Director Tim Childs was the last director to join the board, commencing their role in 2022.Reported Earnings • Jun 02Second quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.06 loss in 2Q 2021)Second quarter 2022 results: CA$0.058 loss per share (up from CA$0.06 loss in 2Q 2021). Revenue: CA$2.02m (down 7.6% from 2Q 2021). Net loss: CA$8.32m (loss narrowed 3.1% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.お知らせ • May 07MPX International Corporation, Annual General Meeting, Jul 15, 2022MPX International Corporation, Annual General Meeting, Jul 15, 2022.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Chairman, President & CEO William Boyes is the most experienced director on the board, commencing their role in 2018. Independent Director Robert Petch was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 04First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.03 loss per share (down from CA$0.016 loss in 1Q 2021). Revenue: CA$1.56m (down 19% from 1Q 2021). Net loss: CA$4.25m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.19 loss per share (up from CA$0.29 loss in FY 2020). Revenue: CA$7.21m (up 127% from FY 2020). Net loss: CA$26.6m (loss narrowed 35% from FY 2020). Revenue was in line with analyst estimates.最新情報をもっと見るRecent updatesBoard Change • Jul 31High number of new directorsIndependent Director Tim Childs was the last director to join the board, commencing their role in 2022.Reported Earnings • Jun 02Second quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.06 loss in 2Q 2021)Second quarter 2022 results: CA$0.058 loss per share (up from CA$0.06 loss in 2Q 2021). Revenue: CA$2.02m (down 7.6% from 2Q 2021). Net loss: CA$8.32m (loss narrowed 3.1% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.お知らせ • May 07MPX International Corporation, Annual General Meeting, Jul 15, 2022MPX International Corporation, Annual General Meeting, Jul 15, 2022.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Chairman, President & CEO William Boyes is the most experienced director on the board, commencing their role in 2018. Independent Director Robert Petch was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 04First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.03 loss per share (down from CA$0.016 loss in 1Q 2021). Revenue: CA$1.56m (down 19% from 1Q 2021). Net loss: CA$4.25m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.19 loss per share (up from CA$0.29 loss in FY 2020). Revenue: CA$7.21m (up 127% from FY 2020). Net loss: CA$26.6m (loss narrowed 35% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Sep 02Third quarter 2021 earnings released: CA$0.013 loss per share (vs CA$0.037 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$1.78m (up 93% from 3Q 2020). Net loss: CA$1.89m (loss narrowed 65% from 3Q 2020).分析記事 • May 31Is MPX International (CSE:MPXI) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 30Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.018 loss in 2Q 2020)The company reported a decent second quarter result with improved revenues, although losses increased and control over costs was weaker. Second quarter 2021 results: Revenue: CA$2.19m (up 174% from 2Q 2020). Net loss: CA$8.59m (loss widened 240% from 2Q 2020).Executive Departure • Apr 17Independent Director has left the companyOn the 16th of April, Randall Stafford's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Randall's name. A total of 2 executives have left over the last 12 months.Reported Earnings • Mar 03First quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.033 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$1.91m (up 210% from 1Q 2020). Net loss: CA$2.26m (loss narrowed 49% from 1Q 2020).分析記事 • Feb 11MPX International (CSE:MPXI) Is Carrying A Fair Bit Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is New 90 Day High Low • Feb 10New 90-day high: CA$0.25The company is up 150% from its price of CA$0.10 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 92% over the same period.Reported Earnings • Feb 01Full year 2020 earnings released: CA$0.29 loss per share (vs CA$0.13 loss in FY 2019)Full year 2020 results: Net loss: CA$41.0m (loss widened 338% from FY 2019).お知らせ • Oct 20MPX International Corporation Appoints Jeremy Blumer as Chief Financial OfficerMPX International Corporation announced the appointment of Jeremy Blumer as the company's new Chief Financial Officer, effective October 16, 2020, subject to regulatory approval. Mr. Blumer brings over 25 years of financial experience with both public and private companies to the Corporation, including in the cannabis industry as CFO with Quality Green Inc. and Wayland Group Corp. (formerly Maricann Group Inc.). Mr. Blumer was also the Senior Director and Head of Accounting at Blackberry and held senior finance positions with Certicom, Ontario Ambulance Services Co and Pilot Insurance.Reported Earnings • Oct 18Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$15.3m, with losses widening by 103% from the prior year.お知らせ • Jun 19MPX International Corporation announced that it expects to receive CAD 5 million in fundingMPX International Corporation (CNSX:MPXI) announced a non-brokered private placement of minimum of 3,000 units for gross proceeds of CAD 4,000,000 and a maximum of 3,700 units for gross proceeds of CAD 5,000,000 on June 18, 2020. Each unit consists of one 12% secured convertible debenture in the principal amount of $1,000.00 (CAD 1,351.3513) and 7,000 common share purchase warrants. The debenture carries a coupon of 12% per annum and will have a maturity date of 24 months from the date of issuance, subject to certain conversion privileges as set forth in a debenture indenture with AST Trust Company (Canada). Each debenture will rank pari passu in right of payment of principal and interest with all other debentures issued under the Offering. The debenture is convertible into common shares of the company at an exercise price of CAD 0.12 per share. Each warrant will entities to the holders to purchase one common shares at CAD 0.20 per share for a period of 24 months. The debentures will be payable quarterly in arrears. The company may pay a cash placement fee equal to 5% of the aggregate gross proceeds paid by each purchaser of units that are invested in the transaction. In addition, the corporation may issue that number of common share purchase warrants equal to 5% of the aggregate number of common shares underlying the debentures if converted as of the closing date and the warrants issued to purchasers of the units excluding the aggregate number units purchased by investors that participated in the corporation’s equity raise which closed in March 2019. The compensation warrants shall be exercisable at the exercise price for a period of 2 years from the applicable closing date of the offering. The transaction is subject to regulatory and Canadian Securities Exchange approval and may occur in multiple tranches. All securities issued in connection with the transaction will be subject to a statutory four-month and one day hold period.株主還元MPXICA PharmaceuticalsCA 市場7Dn/a-5.6%1.4%1Yn/a55.8%31.6%株主還元を見る業界別リターン: MPXIがCanadian Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MPXI Canadian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MPXI's price volatile compared to industry and market?MPXI volatilityMPXI Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.8%Market Average Movement10.1%10% most volatile stocks in CA Market17.5%10% least volatile stocks in CA Market3.7%安定した株価: MPXI 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のMPXIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aWilliam Boyesmpxinternationalcorp.comMPXインターナショナル・コーポレーションは、カナダおよび海外で大麻会社として事業を展開している。HOLYWEED、beleaf、SALSUS、MPX labs、Canveda、SPARTAN WELLNESS、HIGH12、STRAIN REE、PENNIES、Kingsway、DAIZE、aliceのブランドで大麻製品を提供している。同社は2015年に設立され、カナダのトロントに本社を置いている。もっと見るMPX International Corporation 基礎のまとめMPX International の収益と売上を時価総額と比較するとどうか。MPXI 基礎統計学時価総額CA$721.61k収益（TTM）-CA$28.36m売上高(TTM)CA$6.69m0.0xP/Sレシオ0.0xPER（株価収益率MPXI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MPXI 損益計算書（TTM）収益CA$6.69m売上原価CA$3.37m売上総利益CA$3.33mその他の費用CA$31.68m収益-CA$28.36m直近の収益報告Mar 31, 2022次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%MPXI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/06 21:44終値2024/04/08 00:00収益2022/03/31年間収益2021/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MPX International Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jul 31High number of new directorsIndependent Director Tim Childs was the last director to join the board, commencing their role in 2022.
Reported Earnings • Jun 02Second quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.06 loss in 2Q 2021)Second quarter 2022 results: CA$0.058 loss per share (up from CA$0.06 loss in 2Q 2021). Revenue: CA$2.02m (down 7.6% from 2Q 2021). Net loss: CA$8.32m (loss narrowed 3.1% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
お知らせ • May 07MPX International Corporation, Annual General Meeting, Jul 15, 2022MPX International Corporation, Annual General Meeting, Jul 15, 2022.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Chairman, President & CEO William Boyes is the most experienced director on the board, commencing their role in 2018. Independent Director Robert Petch was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 04First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.03 loss per share (down from CA$0.016 loss in 1Q 2021). Revenue: CA$1.56m (down 19% from 1Q 2021). Net loss: CA$4.25m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.19 loss per share (up from CA$0.29 loss in FY 2020). Revenue: CA$7.21m (up 127% from FY 2020). Net loss: CA$26.6m (loss narrowed 35% from FY 2020). Revenue was in line with analyst estimates.
Board Change • Jul 31High number of new directorsIndependent Director Tim Childs was the last director to join the board, commencing their role in 2022.
Reported Earnings • Jun 02Second quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.06 loss in 2Q 2021)Second quarter 2022 results: CA$0.058 loss per share (up from CA$0.06 loss in 2Q 2021). Revenue: CA$2.02m (down 7.6% from 2Q 2021). Net loss: CA$8.32m (loss narrowed 3.1% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
お知らせ • May 07MPX International Corporation, Annual General Meeting, Jul 15, 2022MPX International Corporation, Annual General Meeting, Jul 15, 2022.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Chairman, President & CEO William Boyes is the most experienced director on the board, commencing their role in 2018. Independent Director Robert Petch was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 04First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.03 loss per share (down from CA$0.016 loss in 1Q 2021). Revenue: CA$1.56m (down 19% from 1Q 2021). Net loss: CA$4.25m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.19 loss per share (up from CA$0.29 loss in FY 2020). Revenue: CA$7.21m (up 127% from FY 2020). Net loss: CA$26.6m (loss narrowed 35% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Sep 02Third quarter 2021 earnings released: CA$0.013 loss per share (vs CA$0.037 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$1.78m (up 93% from 3Q 2020). Net loss: CA$1.89m (loss narrowed 65% from 3Q 2020).
分析記事 • May 31Is MPX International (CSE:MPXI) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 30Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.018 loss in 2Q 2020)The company reported a decent second quarter result with improved revenues, although losses increased and control over costs was weaker. Second quarter 2021 results: Revenue: CA$2.19m (up 174% from 2Q 2020). Net loss: CA$8.59m (loss widened 240% from 2Q 2020).
Executive Departure • Apr 17Independent Director has left the companyOn the 16th of April, Randall Stafford's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Randall's name. A total of 2 executives have left over the last 12 months.
Reported Earnings • Mar 03First quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.033 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$1.91m (up 210% from 1Q 2020). Net loss: CA$2.26m (loss narrowed 49% from 1Q 2020).
分析記事 • Feb 11MPX International (CSE:MPXI) Is Carrying A Fair Bit Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Is New 90 Day High Low • Feb 10New 90-day high: CA$0.25The company is up 150% from its price of CA$0.10 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 92% over the same period.
Reported Earnings • Feb 01Full year 2020 earnings released: CA$0.29 loss per share (vs CA$0.13 loss in FY 2019)Full year 2020 results: Net loss: CA$41.0m (loss widened 338% from FY 2019).
お知らせ • Oct 20MPX International Corporation Appoints Jeremy Blumer as Chief Financial OfficerMPX International Corporation announced the appointment of Jeremy Blumer as the company's new Chief Financial Officer, effective October 16, 2020, subject to regulatory approval. Mr. Blumer brings over 25 years of financial experience with both public and private companies to the Corporation, including in the cannabis industry as CFO with Quality Green Inc. and Wayland Group Corp. (formerly Maricann Group Inc.). Mr. Blumer was also the Senior Director and Head of Accounting at Blackberry and held senior finance positions with Certicom, Ontario Ambulance Services Co and Pilot Insurance.
Reported Earnings • Oct 18Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$15.3m, with losses widening by 103% from the prior year.
お知らせ • Jun 19MPX International Corporation announced that it expects to receive CAD 5 million in fundingMPX International Corporation (CNSX:MPXI) announced a non-brokered private placement of minimum of 3,000 units for gross proceeds of CAD 4,000,000 and a maximum of 3,700 units for gross proceeds of CAD 5,000,000 on June 18, 2020. Each unit consists of one 12% secured convertible debenture in the principal amount of $1,000.00 (CAD 1,351.3513) and 7,000 common share purchase warrants. The debenture carries a coupon of 12% per annum and will have a maturity date of 24 months from the date of issuance, subject to certain conversion privileges as set forth in a debenture indenture with AST Trust Company (Canada). Each debenture will rank pari passu in right of payment of principal and interest with all other debentures issued under the Offering. The debenture is convertible into common shares of the company at an exercise price of CAD 0.12 per share. Each warrant will entities to the holders to purchase one common shares at CAD 0.20 per share for a period of 24 months. The debentures will be payable quarterly in arrears. The company may pay a cash placement fee equal to 5% of the aggregate gross proceeds paid by each purchaser of units that are invested in the transaction. In addition, the corporation may issue that number of common share purchase warrants equal to 5% of the aggregate number of common shares underlying the debentures if converted as of the closing date and the warrants issued to purchasers of the units excluding the aggregate number units purchased by investors that participated in the corporation’s equity raise which closed in March 2019. The compensation warrants shall be exercisable at the exercise price for a period of 2 years from the applicable closing date of the offering. The transaction is subject to regulatory and Canadian Securities Exchange approval and may occur in multiple tranches. All securities issued in connection with the transaction will be subject to a statutory four-month and one day hold period.
